NO326459B1 - Isolert polynukleotidmolekyl, ekspresjonsvektor, dyrket celle i hvilken det er innfort en ekspresjonsvektor, fremgangsmate for fremstilling av et FGF-homolog-polypeptid, farmasoytisk preparat, antistoff, anvendelse av en forbindelse for fremstilling av et medikament for stimulering av proliferasjon av myocytter eller myocyttforlopere, fremgangsmate for eks vivo-stimulering av myocyttforloperceller eller myocytter og anvendelse av en forbindelse for fremstilling av et medikament for levering av et middel eller legemiddel til hjertevev. - Google Patents

Isolert polynukleotidmolekyl, ekspresjonsvektor, dyrket celle i hvilken det er innfort en ekspresjonsvektor, fremgangsmate for fremstilling av et FGF-homolog-polypeptid, farmasoytisk preparat, antistoff, anvendelse av en forbindelse for fremstilling av et medikament for stimulering av proliferasjon av myocytter eller myocyttforlopere, fremgangsmate for eks vivo-stimulering av myocyttforloperceller eller myocytter og anvendelse av en forbindelse for fremstilling av et medikament for levering av et middel eller legemiddel til hjertevev. Download PDF

Info

Publication number
NO326459B1
NO326459B1 NO19991796A NO991796A NO326459B1 NO 326459 B1 NO326459 B1 NO 326459B1 NO 19991796 A NO19991796 A NO 19991796A NO 991796 A NO991796 A NO 991796A NO 326459 B1 NO326459 B1 NO 326459B1
Authority
NO
Norway
Prior art keywords
amino acid
polypeptide
acid residue
seq
fgf
Prior art date
Application number
NO19991796A
Other languages
English (en)
Norwegian (no)
Other versions
NO991796L (no
NO991796D0 (no
Inventor
Theresa A Deisher
Darrell C Conklin
Fenella Raymond
Thomas R Bukowski
Susan D Holderman
Birgit Hansen
Paul O Sheppard
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of NO991796D0 publication Critical patent/NO991796D0/no
Publication of NO991796L publication Critical patent/NO991796L/no
Publication of NO326459B1 publication Critical patent/NO326459B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
NO19991796A 1996-10-16 1999-04-15 Isolert polynukleotidmolekyl, ekspresjonsvektor, dyrket celle i hvilken det er innfort en ekspresjonsvektor, fremgangsmate for fremstilling av et FGF-homolog-polypeptid, farmasoytisk preparat, antistoff, anvendelse av en forbindelse for fremstilling av et medikament for stimulering av proliferasjon av myocytter eller myocyttforlopere, fremgangsmate for eks vivo-stimulering av myocyttforloperceller eller myocytter og anvendelse av en forbindelse for fremstilling av et medikament for levering av et middel eller legemiddel til hjertevev. NO326459B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2864696P 1996-10-16 1996-10-16
PCT/US1997/018635 WO1998016644A1 (en) 1996-10-16 1997-10-16 Fibroblast growth factor homologs

Publications (3)

Publication Number Publication Date
NO991796D0 NO991796D0 (no) 1999-04-15
NO991796L NO991796L (no) 1999-06-16
NO326459B1 true NO326459B1 (no) 2008-12-08

Family

ID=21844629

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991796A NO326459B1 (no) 1996-10-16 1999-04-15 Isolert polynukleotidmolekyl, ekspresjonsvektor, dyrket celle i hvilken det er innfort en ekspresjonsvektor, fremgangsmate for fremstilling av et FGF-homolog-polypeptid, farmasoytisk preparat, antistoff, anvendelse av en forbindelse for fremstilling av et medikament for stimulering av proliferasjon av myocytter eller myocyttforlopere, fremgangsmate for eks vivo-stimulering av myocyttforloperceller eller myocytter og anvendelse av en forbindelse for fremstilling av et medikament for levering av et middel eller legemiddel til hjertevev.

Country Status (20)

Country Link
US (3) US5989866A (ko)
EP (4) EP2264175B1 (ko)
JP (1) JP4091122B2 (ko)
KR (1) KR100611063B1 (ko)
CN (1) CN1127568C (ko)
AT (2) ATE491029T1 (ko)
AU (1) AU725551B2 (ko)
BR (2) BRPI9712348C8 (ko)
CA (1) CA2269083C (ko)
CZ (1) CZ299288B6 (ko)
DE (2) DE69740074D1 (ko)
DK (2) DK0931148T3 (ko)
ES (3) ES2403880T3 (ko)
HK (2) HK1089206A1 (ko)
IL (1) IL129379A (ko)
NO (1) NO326459B1 (ko)
PL (1) PL192537B1 (ko)
PT (2) PT1632574E (ko)
UA (1) UA75316C2 (ko)
WO (1) WO1998016644A1 (ko)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728546A (en) 1995-06-05 1998-03-17 Human Genome Sciences, Inc. Fibroblast growth factor 13
US20050043234A1 (en) * 1996-10-16 2005-02-24 Deisher Theresa A. Novel FGF homologs
US6518236B1 (en) * 1996-10-16 2003-02-11 Zymogenetics, Inc. FGF homologs
EP0942981A1 (en) * 1996-11-27 1999-09-22 Human Genome Sciences, Inc. Fibroblast growth factor-13
US6207442B1 (en) * 1997-10-16 2001-03-27 Zymogenetics, Inc. Plasmid construction by homologous recombination
EP1062339A2 (en) * 1998-03-09 2000-12-27 Chiron Corporation Human fgf gene and gene expression products
EP1061943B1 (en) * 1998-03-12 2002-10-23 Genentech, Inc. Use of fgf-5 polypeptides for preventing the death of retinal neurons and treating ocular diseases
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
AU5081899A (en) * 1998-07-20 2000-02-14 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6251079B1 (en) 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
EP1218026B1 (en) * 1999-09-30 2004-03-31 Kaken Pharmaceutical Co., Ltd. Preparation of a medicament to enhance healing of the sternum after sternotomy
US7470665B2 (en) 1999-12-02 2008-12-30 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or -2
AU1804201A (en) * 1999-12-02 2001-06-12 Zymogenetics Inc. Methods for targeting cells that express fibroblast growth receptor-3 or-2
US7288521B2 (en) * 2000-04-06 2007-10-30 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
US7291597B2 (en) * 2000-04-06 2007-11-06 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
IL139380A0 (en) * 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
WO2003012053A2 (en) * 2001-08-01 2003-02-13 New York University Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis
JP4246069B2 (ja) * 2001-12-28 2009-04-02 協和発酵キリン株式会社 関節炎の治療薬
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
ATE312605T1 (de) * 2002-06-29 2005-12-15 Aquanova Ger Solubilisate Tech Isoflavonkonzentrate sowie verfahren zu ihrer herstellung
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7482427B2 (en) * 2002-08-20 2009-01-27 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
JP4754823B2 (ja) * 2002-10-07 2011-08-24 ザイモジェネティクス， インコーポレイテッド Ｆｇｆ１８の投与方法
US20080194472A1 (en) * 2003-03-27 2008-08-14 Jeffrey Allen Whitsett Use of Fgf-18 Protein, Target Proteins and Their Respective Encoding Nucleotide Sequences to Induce Cartilage Formation
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
EP1896053B1 (en) 2004-07-06 2018-10-31 ZymoGenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
CA2592261C (en) * 2004-12-10 2015-11-24 Zymogenetics Inc. Fgf18 production in prokaryotic hosts
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
US8921109B2 (en) 2005-09-19 2014-12-30 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
WO2007099953A1 (ja) * 2006-02-28 2007-09-07 National University Corporation Tokyo Medical And Dental University 歯根形成促進剤及び歯根形成促進方法
CA2649729A1 (en) * 2006-04-17 2007-10-25 Hepacore Ltd. Methods for bone regeneration using endothelial progenitor cell preparations
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
WO2007150053A2 (en) 2006-06-22 2007-12-27 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
US8962556B2 (en) * 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
US7776825B1 (en) * 2006-11-09 2010-08-17 Florida State University Research Foundation, Incorporated Mutant polypeptides of fibroblast growth factor 1
WO2008102783A1 (ja) * 2007-02-19 2008-08-28 National Institute Of Advanced Industrial Science And Technology 発毛促進剤
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
US7659379B1 (en) * 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
CA2717725A1 (en) 2008-03-05 2009-09-11 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
US10221456B2 (en) 2012-08-06 2019-03-05 Merck Patent Gmbh Genetic markers for predicting responsiveness to FPG-18 compound
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
KR102261934B1 (ko) * 2015-01-23 2021-06-08 (주) 에스바이오메딕스 Mbp-fgf2를 이용한 3차원 섬유아세포집합체를 제조하는 방법
CN107209177A (zh) 2015-01-29 2017-09-26 阿雷斯贸易股份有限公司 用于高正电荷蛋白的免疫测定法
JP6951318B2 (ja) * 2015-07-15 2021-10-20 プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド 融合ポリペプチドおよび使用方法
MX2020003211A (es) 2017-09-21 2020-09-21 Merck Patent Gmbh Proteina de fusion que comprende una porcion de fgf-18.
JP7418324B2 (ja) 2017-09-29 2024-01-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆｇｆ－１８化合物に対する反応性を予測する炎症バイオマーカー
HRP20220760T1 (hr) 2017-09-29 2022-09-02 Merck Patent Gmbh Metabolički biomarkeri za predviđanje odgovaranja na spoj fgf-18
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE54046B1 (en) 1981-08-25 1989-05-24 Celltech Ltd Expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4945778A (en) 1984-01-30 1990-08-07 Weyer Paul P Fluid-power device with rollers
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
DE3578435D1 (de) 1984-12-06 1990-08-02 Labofina Sa Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5439818A (en) * 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
US5604293A (en) * 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CA2144651A1 (en) 1992-09-14 1994-03-31 Timothy J. Miller Immortalized cells and uses therefor
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
US5965389A (en) 1995-11-09 1999-10-12 Zymogenetics, Inc. Production of GAD65 in methylotrophic yeast

Also Published As

Publication number Publication date
DE69740074D1 (de) 2011-01-20
CZ299288B6 (cs) 2008-06-04
EP2339002A1 (en) 2011-06-29
PL332851A1 (en) 1999-10-25
PT1632574E (pt) 2011-03-17
ATE318906T1 (de) 2006-03-15
DK1632574T3 (da) 2011-02-28
CZ131599A3 (cs) 1999-11-17
ATE491029T1 (de) 2010-12-15
IL129379A (en) 2008-12-29
AU4758397A (en) 1998-05-11
EP1632574A1 (en) 2006-03-08
JP4091122B2 (ja) 2008-05-28
ES2403880T3 (es) 2013-05-22
ES2357215T3 (es) 2011-04-20
EP2264175B1 (en) 2012-11-21
JP2001502178A (ja) 2001-02-20
WO1998016644A1 (en) 1998-04-23
DK0931148T3 (da) 2006-06-19
PL192537B1 (pl) 2006-11-30
KR100611063B1 (ko) 2006-08-09
HK1148030A1 (en) 2011-08-26
IL129379A0 (en) 2000-02-17
NO991796L (no) 1999-06-16
US20040096936A1 (en) 2004-05-20
CA2269083C (en) 2009-06-09
KR20000049207A (ko) 2000-07-25
BRPI9712348C8 (pt) 2020-04-22
EP0931148B1 (en) 2006-03-01
NO991796D0 (no) 1999-04-15
CA2269083A1 (en) 1998-04-23
BR9712348A (pt) 1999-08-31
DE69735352D1 (de) 2006-04-27
UA75316C2 (uk) 2006-04-17
EP0931148A1 (en) 1999-07-28
US5989866A (en) 1999-11-23
BR9712348B1 (pt) 2013-06-18
DE69735352T2 (de) 2006-10-12
ES2258788T3 (es) 2006-09-01
EP1632574B1 (en) 2010-12-08
US7247608B2 (en) 2007-07-24
US6352971B1 (en) 2002-03-05
HK1089206A1 (en) 2006-11-24
PT931148E (pt) 2006-06-30
CN1247568A (zh) 2000-03-15
AU725551B2 (en) 2000-10-12
CN1127568C (zh) 2003-11-12
EP2264175A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
NO326459B1 (no) Isolert polynukleotidmolekyl, ekspresjonsvektor, dyrket celle i hvilken det er innfort en ekspresjonsvektor, fremgangsmate for fremstilling av et FGF-homolog-polypeptid, farmasoytisk preparat, antistoff, anvendelse av en forbindelse for fremstilling av et medikament for stimulering av proliferasjon av myocytter eller myocyttforlopere, fremgangsmate for eks vivo-stimulering av myocyttforloperceller eller myocytter og anvendelse av en forbindelse for fremstilling av et medikament for levering av et middel eller legemiddel til hjertevev.
US20080233114A1 (en) Novel fgf homologs
WO2001049849A1 (en) Novel fgf homolog zfgf11
US20020081663A1 (en) Novel FGF homolog ZFGF11
US20080124759A1 (en) Novel fgf homolog zfgf12
EP1246843A1 (en) Novel fgf homolog zfgf12
US8349590B2 (en) FGF homologs compositions and uses thereof
US7135459B2 (en) Methods of use of FGF homologs
MXPA99003530A (es) Homologos del factor de crecimiento de fibroblastos
US20020031805A1 (en) Novel FGF homolog zFGF10
WO2001047957A2 (en) Human fgf-10- (kgf-2)-like protein zfgf-10

Legal Events

Date Code Title Description
MK1K Patent expired